1.17
-0.03 (-2.5%)
-0.03 (-2.5%)
Upgrade to Real-Time
Regular Market
| Volume | 22,373 |
|
|||||
| News | (1) | ||||||
| Day High | 1.21 | Low High |
|||||
| Day Low | 1.1509 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Equillium Inc | EQ | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.03 | -2.5% | 1.17 | 10:40:09 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.19 | 1.1509 | 1.21 | 1.20 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 87 | 22,373 | $ 1.18 | $ 26,298 | - | 0.790001 - 4.3799 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:40:09 | 1 | $ 1.185 | USD |
Period:
Draw Mode:
Equillium Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 40.26M | 34.41M | 17.20M | $ - | $ - | -1.36 | -0.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 1.18M | 3.70% |
Equillium News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EQ Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.00 | 1.35 | 0.987 | 1.18 | 738,564 | 0.17 | 17.0% |
| 1 Month | 1.15 | 1.35 | 0.98 | 1.16 | 255,531 | 0.02 | 1.74% |
| 3 Months | 1.69 | 1.88 | 0.790001 | 1.16 | 130,483 | -0.52 | -30.77% |
| 6 Months | 2.33 | 3.20 | 0.790001 | 1.92 | 170,384 | -1.16 | -49.79% |
| 1 Year | 4.09 | 4.3799 | 0.790001 | 2.07 | 102,813 | -2.92 | -71.39% |
| 3 Years | 4.86 | 30.20 | 0.790001 | 16.55 | 594,912 | -3.69 | -75.93% |
| 5 Years | 14.35 | 30.20 | 0.790001 | 16.33 | 425,059 | -13.18 | -91.85% |
Equillium Description
| Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. |